NSs (non-structural) protein suppresses type I interferon response
Interferon antagonism allows viral replication to proceed
IFNAR knockout mice have markedly increased susceptibility
Cytopenia mechanism
Leukopenia and thrombocytopenia result from viral suppression of hematopoiesis
Direct viral infection of bone marrow progenitors suspected
Recovery of cytopenias parallels viral clearance
Severe disease pathway
Multiorgan failure in fatal cases
Hemorrhagic disease with DIC (less prominent than SFTS)
Encephalopathy mechanism may involve direct CNS viral invasion or inflammatory mediators
Therapeutic Considerations
Evidence base for management
Antiviral research status
No FDA-approved antiviral; management is supportive
Favipiravir inhibits HRTV replication in vitro and in vivo murine models
4'-fluorouridine (EIDD-2749) demonstrated efficacy in mouse models (Westover et al., 2024)
Ribavirin studied in IFNAR knockout mouse model (Fujii et al., 2022)
Doxycycline rationale
Indicated empirically to cover bacterial mimics (ehrlichiosis, anaplasmosis)
No direct antiviral activity against HRTV
Should be reassessed once diagnostic results available
Immune modulation considerations
Corticosteroids not routinely recommended
Immunosuppression may worsen viral replication based on animal data
Avoid immunosuppressive agents unless compelling alternative indication
Natural history
Clinical course
Illness typically lasts 2–4 weeks in survivors
Cytopenias recover after viral clearance
Full recovery expected in most immunocompetent patients
Prognostic factors
Age > 70 years with comorbidities most strongly associated with mortality
Multiorgan failure portends poor prognosis
Immunosuppression likely increases severity
Patient Discharge Instructions
copy discharge instructions
Heartland virus discharge instructions
About your illness
Heartland virus is a rare tick-borne viral infection with no specific antiviral treatment
Recovery takes weeks; fatigue and weakness are common during convalescence
You will need follow-up blood tests to confirm your counts are recovering
Follow-up appointments
Blood recheck (CBC and liver tests) within 3–5 days of leaving hospital
Return to your doctor if results are not improving
Notify your doctor of any new symptoms during recovery
Activity and diet
Rest as needed; gradually increase activity as energy returns
Drink plenty of fluids; aim for clear, pale urine
Bland diet if nausea persists; avoid alcohol during recovery
No contact sports or activities with bleeding risk until platelets fully recovered
Medications to avoid
Do not take ibuprofen, naproxen, aspirin, or any NSAID until blood counts are normal
Avoid blood-thinning medications unless specifically directed by your physician
Acetaminophen (Tylenol) is safe for fever and pain at recommended doses
Return to emergency department immediately for
Fever returning after discharge
New or worsening confusion, difficulty thinking, or unusual behaviour
Any bleeding: gums, nose, urine (pink or red), stool (black or red), unusual bruising
Inability to keep fluids down
Worsening fatigue, dizziness, or feeling faint
Severe headache or stiff neck
Tick prevention after recovery
Wear long sleeves and pants in wooded or grassy areas
Apply DEET-based repellent to exposed skin
Apply permethrin to clothing and gear before outdoor activities
Perform full-body tick checks after outdoor exposure
Shower promptly and dry clothing at high heat after potential tick contact
Reporting
Heartland virus is a reportable infection; your case has been reported to the health department
Family members or coworkers with similar symptoms after the same outdoor exposure should seek medical evaluation
References
Guidelines and key sources
Primary literature
McMullan LK, Folk SM, Kelly AJ, et al. A New Phlebovirus Associated with Severe Febrile Illness in Missouri. N Engl J Med. 2012
Index case description of Heartland virus
Characterized temporal evolution of cytopenias and transaminases
Staples JE, Pastula DM, Panella AJ, et al. Investigation of Heartland Virus Disease Throughout the United States, 2013-2017. Open Forum Infect Dis. 2020
60+ cases across 14 states
88% hospitalization rate; 10–13% mortality
Pastula DM, Turabelidze G, Yates KF, et al. Notes From the Field: Heartland Virus Disease - United States, 2012-2013. MMWR. 2014
Early surveillance data
Epidemiologic characteristics of early confirmed cases
Muehlenbachs A, Fata CR, Lambert AJ, et al. Heartland Virus-Associated Death in Tennessee. Clin Infect Dis. 2014
Fatal case pathology and autopsy findings
HRTV antigen in lymph nodes
Westover JB, Jung KH, Alkan C, et al. Modeling Heartland Virus Disease in Mice and Therapeutic Intervention With 4'-Fluorouridine. J Virol. 2024
EIDD-2749 efficacy in murine model
Characterizes nadir and recovery of cytopenias
Serologic and diagnostic references
Basile AJ, Horiuchi K, Goodman CH, et al. Development of Diagnostic Microsphere-Based Immunoassays for Heartland Virus. J Clin Virol. 2021
CDC microsphere immunoassays with > 95% sensitivity and specificity
IgM and IgG detection methodology
Brault AC, Savage HM, Duggal NK, Eisen RJ, Staples JE. Heartland Virus Epidemiology, Vector Association, and Disease Potential. Viruses. 2018
Vector competence data for Amblyomma americanum
Reservoir host seroprevalence
Clinical practice guidelines
Ho BM, Davis HE, Forrester JD, et al. Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Management of Tick-Borne Illness in the United States. Wilderness Environ Med. 2021
Tick-borne illness prevention and management framework
Doxycycline empiric therapy guidance
CDC Tickborne Diseases of the United States: A Reference Manual for Healthcare Providers, 6th Edition. 2022
Comprehensive tick-borne illness reference
Reporting requirements and public health guidance
Feng K, Bendiwhobel Ushie B, Zhang H, et al. Pathogenesis and Virulence of Heartland Virus. Virulence. 2024
Interferon antagonism by NSs protein
Molecular mechanisms of HRTV pathogenesis
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.